Skip to Content

Alprolix Approval History

FDA Approved: Yes (First approved March 28, 2014)
Brand name: Alprolix
Generic name: coagulation factor IX (recombinant)
Company: Biogen
Treatment for: Hemophilia B

Alprolix (coagulation factor IX (recombinant)) is a clotting factor IX therapy indicated to prevent bleeding in patients with hemophilia B.

Development History and FDA Approval Process for Alprolix

DateArticle
Mar 28, 2014Approval FDA Approves Alprolix (recombinant coagulation factor IX) for patients with Hemophilia B

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide